Provided is a novel compound having a selective activating effect on ERβ. The present invention provides a compound represented by the following formula (1) wherein R.sup.1 represents a cycloalkyl group having 3 to 8 carbon atoms, an alkenyl group having 2 to 6 carbon atoms and optionally substituted with a halogen atom, a 5-membered nitrogen-containing heteroaryl group, a 4- to 6-membered cyclic amino group, an alkanoylamino group having 2 to 6 carbon atoms and optionally substituted with a halogen atom, a 1-trifluoromethyl-1-hydroxymethyl group, or a 1-methylpropyl group; R.sup.2 to R.sup.5 are the same or different and each represent a hydrogen atom or a fluorine atom; and R.sup.6 represents a hydrogen atom or an alkanoyl group having 2 to 5 carbon atoms, or a salt thereof.

##STR00001##

The composition contains: a compound which has a group represented by formula (1); and a solvent. In the formula (1), R.sup.1 and R.sup.2 each independently represent a substituted or unsubstituted aryl group having 6 to 30 ring atoms or a substituted or unsubstituted heteroaryl group having 5 to 30 ring atoms; R.sup.3 represents a hydrogen atom or a substituted or unsubstituted monovalent aliphatic hydrocarbon group having 1 to 10 carbon atoms; and * denotes a bonding site to a part other than the group represented by the following formula (1) in the compound.

##STR00001##

The composition contains: a compound which has a group represented by formula (1); and a solvent. In the formula (1), R.sup.1 and R.sup.2 each independently represent a substituted or unsubstituted aryl group having 6 to 30 ring atoms or a substituted or unsubstituted heteroaryl group having 5 to 30 ring atoms; R.sup.3 represents a hydrogen atom or a substituted or unsubstituted monovalent aliphatic hydrocarbon group having 1 to 10 carbon atoms; and * denotes a bonding site to a part other than the group represented by the following formula (1) in the compound.

##STR00001##

The present invention relates to crystalline polymorphs of Tapinarof, e.g., Tapinarof crystalline Form B, Form C, and Form D, pharmaceutical compositions comprising the same, processes for preparation thereof, and uses thereof for treatment of skin disorders.

Compositions of Δ10-THC and Δ6a10a-THC are prepared and described. The conversions do not affect existing CBD or CBG in the extract. Various adjustments can be made to the reactions resulting in increased or decreased product and by-product. Various formulations with medical uses are disclosed.

Compositions of Δ10-THC and Δ6a10a-THC are prepared and described. The conversions do not affect existing CBD or CBG in the extract. Various adjustments can be made to the reactions resulting in increased or decreased product and by-product. Various formulations with medical uses are disclosed.

A system and method for crystallization and pelleting of a cannabinoid, including cannabidiol (CBD).

Methods of isolating phenols from phenol-containing media. The methods include combining a phospholipid-containing composition with the phenol-containing medium to generate a combined medium, incubating the combined medium to precipitate phenols in the combined medium and thereby form a phenol precipitate phase and a phenol-depleted phase, and separating the phenol precipitate phase and the phenol-depleted phase. The methods can further include extracting phenols from the separated phenol precipitate phase. The extracting can include mixing the separated phenol precipitate phase with an extraction solvent to solubilize in the extraction solvent at least a portion of the phenols originally present in the phenol precipitate phase.

Methods of isolating phenols from phenol-containing media. The methods include combining a phospholipid-containing composition with the phenol-containing medium to generate a combined medium, incubating the combined medium to precipitate phenols in the combined medium and thereby form a phenol precipitate phase and a phenol-depleted phase, and separating the phenol precipitate phase and the phenol-depleted phase. The methods can further include extracting phenols from the separated phenol precipitate phase. The extracting can include mixing the separated phenol precipitate phase with an extraction solvent to solubilize in the extraction solvent at least a portion of the phenols originally present in the phenol precipitate phase.

The present invention relates to a process for recovering and purifying resveratrol produced by microbial fermentation. More particularly, the present invention relates to a process for recovering and purifying resveratrol produced by yeast fermentation.